go back

Casirivimab and Imdevimab Administration, Home or Residence

Delaware rates for HCPCS M0244

Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency

Rates data updated July 2026.

Insurance Carrier